Clinical lung cancer | 2021

Racial Differences in Lung Cancer Screening Beliefs and Screening Adherence.

 
 
 
 
 
 
 
 
 
 

Abstract


BACKGROUND\nOne challenge in high-quality lung cancer screening (LCS) is maintaining adherence with annual and short-interval follow-up screens among high-risk individuals who have undergone baseline low-dose CT (LDCT). This study aimed to characterize attitudes and beliefs toward lung cancer and LCS and to identify factors associated with LCS adherence.\n\n\nMETHODS\nWe administered a questionnaire to 269 LCS participants to assess attitudes and beliefs toward lung cancer and LCS. Clinical data including sociodemographics and screening adherence were obtained from the LCS Program Registry.\n\n\nRESULTS\nAfrican-American individuals had significantly greater lung cancer worries compared with Whites (6.10 vs. 4.66, P < .001). In making the decision to undergo LCS, African-American participants described screening convenience and cost as very important factors significantly more frequently than Whites (60% vs. 26.8%, P< .001 and 58.4% vs. 37.8%, P\xa0=\xa0.001; respectively). African-American individuals with greater than high school education had significantly higher odds of LCS adherence (aOR 2.55; 95% CI, 1.14-5.60) than Whites with less than high school education. Participants who described screening convenience and cost as very important had significantly lower odds of completing screening follow-up after adjusting for demographic and other factors (aOR 0.56; 95% CI, 0.33-0.97 and aOR 0.54; 95% CI, 0.33-0.91, respectively).\n\n\nCONCLUSION\nRacial differences in beliefs about lung cancer and LCS exist among African-American and White individuals enrolled in an LCS program. Cost, convenience, and low educational attainment may be barriers to LCS adherence, specifically among African-American individuals.\n\n\nIMPACT\nMore research is needed on how barriers can be overcome to improve LCS adherence.

Volume None
Pages None
DOI 10.1016/j.cllc.2021.06.003
Language English
Journal Clinical lung cancer

Full Text